Medicenna Therapeutics Corp at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Thanks for joining our next session. My name is Matt Biegler; I'm an analyst on the emerging biotech team here at Oppenheimer. Pleased to introduce our next company, Medicenna, which I'm actually covering with an outperform rating. These guys are developing novel cytokine-based therapies including a novel IL-2 agonist called MDNA11, which you will hear more about.
Just a quick housekeeping note. If you want to ask a question, please type it into the box on the Wall Street Webcasting interface. I think it's at the right-hand side of your screen. So we are joined by CEO, Fahar Merchant. Fahar, the floor is yours.
Thank you, Matt. Thank you all for joining today's presentation for Medicenna. We will be presenting and putting out some forward-looking statements, so I would encourage you to look at our regulatory filings regarding risk factors, et cetera.
So Medicenna is a company that's really focused on developing and designing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
